IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...
(RTTNews) - Edwards Lifesciences Corp. (EW) on Tuesday said its SAPIEN M3 mitral valve replacement system received U.S. Food and Drug Administration (FDA) approval for the treatment of mitral ...
Edwards today presented new data at New York Valves 2026 supporting its transcatheter aortic valve replacement (TAVR) ...
Edwards Lifesciences Corp. today announced that it received CE Mark approval, the European equivalent of the Food and Drug Administration, for its Sapien M3 mitral replacement system. The device ...
Edwards Lifesciences’ SAPIEN M3 mitral valve replacement system has become the first transcatheter therapy utilizing a transseptal approach to snag FDA approval in the U.S. for the treatment of mitral ...
In late June 2026, Edwards Lifesciences presented extensive new clinical data at the New York Valves conference, reinforcing ...
The FDA has approved Edwards Lifesciences Corp.’s Sapien M3 transcatheter mitral valve replacement system. The U.S. approval, announced last week, comes eight months after the device received CE Mark ...
EVOQUE tricuspid valve registry demonstrates more favorable outcomes than pivotal trial SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced data demonstrating successful patient ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results